At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Dexamethasone, and 4 other interventions for Prostate Cancer. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine if the combination of chemotherapy and hormone therapy is safe and helpful for patients who plan to have their high-risk prostate cancer surgically removed. Some physicians believe that patients with high risk cancer that is located in one area, may have an early but small spread of the cancer outside of the prostate, and perhaps even to distant organs. Therefore, better treatments for the entire body are needed to improve the ability of surgery or other local therapies to cure prostate cancer. Since chemotherapy is beginning to demonstrate increasing activity in advanced prostate cancer patients, it is possible that using chemotherapy combined with hormonal therapy earlier in the course of localized but high risk patients might improve the outcomes for these patients.
Study Details
Timeline
Interventions
Given by an IV infusion over 1 hour on day 2 of a three-week cycle
Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
Taken orally three times a day for 5 days for the first part of every three week cycle
Given subcutaneously for 4 doses every three months
Taken orally once a day for 6 months
after the chemo and hormonal therapy all patients have a radiacal prostatectomy